# A Phase 2 Study of Intravenous or Subcutaneous Dosing of Sotatercept (ACE-011) in Patients With End-Stage Kidney Disease on Hemodialysis

> **NCT01999582** · PHASE2 · COMPLETED · sponsor: **Celgene** · enrollment: 50 (actual)

## Conditions studied

- Anemia
- Kidney Failure, Chronic

## Interventions

- **BIOLOGICAL:** Sotatercept
- **BIOLOGICAL:** Sotatercept

## Key facts

- **NCT ID:** NCT01999582
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-11-30
- **Primary completion:** 2016-08-31
- **Final completion:** 2016-08-31
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2024-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01999582

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01999582, "A Phase 2 Study of Intravenous or Subcutaneous Dosing of Sotatercept (ACE-011) in Patients With End-Stage Kidney Disease on Hemodialysis". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01999582. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*